- ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients
- ION582 was safe and well tolerated at all dose levels
- Ionis plans … [+10050 chars]
Lifestyle Natural Medicines
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
(marketscreener.com) ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patientsION582 was safe and well tolerated at all dose levelsIonis plans to move ION582 into pivotal trial Detailed ION582 data
![Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome](https://img.easybranches.com/uploads/news/2024/05/14550176.jpg)
Related
Share this page
Guest Posts by Easy Branches